Celldex Therapeutics
Celldex Therapeutics Inc is an American clinical-stage biopharmaceutical company developing antibody-based therapeutics for inflammatory and allergic diseases. The company develops targeted monoclonal antibodies, including lead candidate barzolvolimab, designed to inhibit KIT receptor tyrosine kinase in mast cell-driven conditions. Main revenue drivers currently comprise investment capital, milestone grants, and development licensing collaborations as clinical candidate testing advances. Celldex Therapeutics targets dermatologists, allergists, clinical research institutions, and patients with chronic urticaria and severe inflammatory disorders across North America. The company holds an innovative position in targeted mast cell therapeutics and inflammatory biopharmaceutical development. Headquartered in Hampton, New Jersey, Celldex Therapeutics Inc is listed on the Nasdaq Stock Market.
5 of the funds FundTelligence covers report a position in Celldex Therapeutics.
- Legal name
- Celldex Therapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 5
- Exposure themes
- Autoimmune diseases, Treatment, Women's Health
Funds holding Celldex Therapeutics
- DNB Bioteknologi — DNB · 0.98 % (full portfolio disclosed, September 2026)
- DNB Fund Women's Health — DNB · 0.95 % (full portfolio disclosed, August 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.03 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.02 % (partially disclosed portfolio, June 2026)
- DNB Global Enhanced Small Cap — DNB · 0.02 % (full portfolio disclosed, September 2026)